ArticleFrontiers in immunology2023

Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.

Jianfeng Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.